Abstract
Background: MicroRNAs are an important regulators of gene expression. They take part in various physiological and cellular processes. Different studies associate distinct expression pattern of miRNAs in lung cancer (LC), COPD and asthma.
The aim in the present study was to analyse expression levels of miR-223 in plasma of patients with non-small cell LCs (NSCLC), COPD or asthma.
Methods: In the current study RNA isolated from plasma of 50 patients - 20 Non SmallCell Lung Carcinomas – 10 squamous cell carcinomas and 10 adenocarcinomas, 15 COPD and 15 asthma patients and 10 healthy controls were included. Reverse transcription for synthesis of cDNA, RT-qPCR and statistical analysis were performed.
Results: Decreased expression was found in 60% of NSCLCs, 64% of asthma, 69% of COPD patients. Overexpression was found in 10% of NSCLC, 7% of asthma and in 15% of COPD. The ROC curve analysis showed that the expression levels of miR-223 may be able to distinguish NSCLCs from healthy individuals - AUC=0.0690, CI 95%:0.453-0.927, p=0.095. The results of current study indicate the lack of statistically significant differences between the expression of miR-223 in plasma samples from LC, asthma and COPD and healthy controls. There were no significant correlations between miR-223 expression and TNM stage, N status, smoking history, asthma control, and COPD severity.
Conclusions: MiR-223 is differently expressed in plasma from LC, COPD and asthma patients. In order to ascertain its role as biomarker for discrimination of patients analysis of enlarged sampling is necessary. Funded by Medical University, Sofia, contract Nr. 90/2016.
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2795.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018